The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1108
July 9, 2001
View Complete Issue         Table of Contents 2019 
Caspofungin (Cancidas) For Aspergillosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Caspofungin (Cancidas) For Aspergillosis
July 9, 2001 (Issue: 1108)
Caspofungin acetate(Cancidas) is the first of a new class of antifungals, the echinocandins. It has been approved by the FDA for treatment of invasive aspergillosis in patients who fail to respond to or are unable to tolerate other antifungal drugs...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Caspofungin (Cancidas) For Aspergillosis
Article code: 1108b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.